La cadena de opciones muestra datos clave de las opciones de acciones de Bit Origin a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Bit Origin..

Bit Origin (NASDAQ:BTOG) Bolsa, Cadena de Opciones

Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.

Dogecoin,Coin,Closeup,Isolated,On,White,Background.,Doge,Front,Side

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

BTOG

Dogecoin (CRYPTO: DOGE) lideraba el grupo de criptomonedas de gran capitalización la mañana del lunes, por delante de Bitcoin (CRYPTO: BTC) y Ethereum (CRYPTO: 

Dogecoin se dispara y lidera el mercado cripto con fuerte volumen e interés inversor

Urban Outfitters

ATCH

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

VTAK

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

Movimiento de acciones

AEHL

AMBC

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

Bit Origin Limited - Class A Ordinary Shares

Bit Origin Ltd

Will redeploy approximately $100 million of capital towards Corporate Payments acquisition
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.corpay.com%2F&amp;esheet=54296289&amp;newsitemid=20250724756251&amp;lan=en-US&amp;anchor=Corpay%2C+Inc.&amp;index=1&amp;md5=449ca0017b394fecd3372047b24900fc">Corpay, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), the corporate payments company, today announced it is divesting one of its legacy lower growth private label fuel card portfolios.
Corpay expects to receive approximately $60 million in proceeds from the divestiture and free up approximately $35 million of working capital. Corpay plans to redeploy the capital towards its acquisition of Alpha Group International plc.
"This transaction is consistent with our plan to remix our portfolio towards higher growth Corporate Payments assets. It demonstrates our discipline to seek contract renewals only when economic terms are attractive," said Ron Clarke, Chairman and CEO of Corpay.
The transaction is expected to close in the fourth quarter of 2025 and represents an immaterial contribution to earnings.

News

CPAY

Corpay To Divest Private Label Fuel Card Portfolio For $60M; Plans $35M Working Capital Shift To Alpha Group Deal

WIIM

FTI Consulting shares are trading higher after the company reported Q2 financial results and beat its EPS and revenue estimates.

RDZN

Roadzen shares are trading higher after the company announced it raised $2.25 million in PIPE financing.

Darling Ingredients shares are trading lower after the company reported worse-than-expected Q2 financial results.

REBN

Reborn Coffee shares are trading higher after the company announced it signed a $1.3 million exclusive licensing agreement with Reborn Health Goods.

<a href="https://www.bloomberg.com/news/articles/2025-07-24/trump-ally-sues-powell-demanding-fomc-meeting-public-access?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-07-24/trump-ally-sues-powell-demanding-fomc-meeting-public-access?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-24/trump-ally-sues-powell-demanding-fomc-meeting-public-access?srnd=homepage-americas</a>

Macro Economic Events

Econ #s

Economics

'Trump Ally Sues Powell Demanding FOMC Meeting Public Access' -Bloomberg

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Stock Yards Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) with a Market Perform and raises the price target from $80 to $85.

Price Target

Analyst Ratings

SYBT

Keefe, Bruyette & Woods Maintains Market Perform on Stock Yards Bancorp, Raises Price Target to $85

Tri Pointe Homes shares are trading lower following Q2 reported financial results.

INBK

First Internet Bancorp shares are trading lower after the company reported mixed Q2 financial results.

Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) reported second-quarter financial results before the market open on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/07/b46596548/valero-energy-reports-second-quarter-2025-results">from the quarter</a>.
Q2 Earnings: Valero Energy reported second-quarter revenue of $29.89 billion, beating analyst <a href="http://benzinga.com/quote/VLO/earnings">estimates</a> of $27.36 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of $2.28 per share, beating estimates of $1.94 per share.
Here&#8217;s a breakdown of operating results by segment:
<ul class="wp-block-list">
<li>Refining: Operating income of $1.3 billion, up from $1.2 billion year-over-year</li>
</ul>
<ul class="wp-block-list">
<li>Ethanol: Operating income of $54 million, down from $105 million year-over-year</li>
</ul>
<ul class="wp-block-list">
<li>Renewable Diesel: Operating loss of $79 million, down from income of $112 million year-over-year</li>
</ul>
&#8220;We delivered solid financial results for the&nbsp;second quarter, driven by our strong operational and commercial execution,&#8221; said Lane Riggs, chairman, president and CEO of Valero.
&#8220;In fact, we set a record for refining throughput rate in our U.S. Gulf Coast region in the&nbsp;second quarter, demonstrating the benefits of our investments in growth and optimization projects.&#8221;
Valero Energy ended the quarter with&nbsp;$4.5 billion&nbsp;of cash and cash equivalents and $8.4 billion of total debt.
VLO Price Action: <a href="http://benzinga.com/quote/VLO">Valero Energy shares</a> were down 4.94% at $140.25 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46598102/top-3-energy-stocks-which-could-rescue-your-portfolio-in-july">Top 3 Energy Stocks Which Could Rescue Your Portfolio In July</a></li>
</ul>
Photo: Shutterstock.

Earnings

Movers

Valero Energy Beats Q2 Earnings Estimates: The Details

First American Financial shares are trading higher after the company reported better-than-expected Q2 financial results.

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) with a Market Perform and raises the price target from $35 to $38.

SMBK

Keefe, Bruyette & Woods Maintains Market Perform on SmartFinancial, Raises Price Target to $38

AGRI

AgriFORCE Growing Systems shares are trading lower after the company announced a 1-for-9 reverse stock split.

Robert Half shares are trading lower following a Q2 EPS miss. JP Morgan cut its price target on the stock from $47 to $45.

IPOs

Accelerant Holdings Shares Open For Trade At $28.50/Share; IPO Priced At $21/Share On 34.46M Shares

Keefe, Bruyette &amp; Woods analyst Kyle Voigt reiterates SEI Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) with a Market Perform and lowers the price target from $100 to $98.

Reiteration

SEIC

Keefe, Bruyette & Woods Reiterates Market Perform on SEI Investments, Lowers Price Target to $98

HTOO

Fusion Fuel Green shares are trading lower after the company announced a $4.3 million private placement.

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial <a target="_blank" href="https://www.benzinga.com/quote/AZN" rel="noreferrer noopener">enrolled 260 patients</a>.
MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction.
In adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis, gefurulimab <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html" target="_blank" rel="noreferrer noopener">met</a> its primary and all secondary endpoints.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698541/johnson-johnsons-new-compelling-data-shows-sustained-symptom-improvement-in-muscular-disease-patients" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s New &#8216;Compelling Data&#8217; Shows Sustained Symptom Improvement In Muscular Disease Patients</a>
Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo.
gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.
Gefurulimab was well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors in gMG with no new safety signals observed. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
In April, Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, the lead cell therapy candidate, in participants with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698463/cartesian-therapeutics-reports-strong-12-month-data-for-lead-cell-therapy-in-myasthenia-gravis-patients" rel="noreferrer noopener">generalized myasthenia gravis</a>.
In March, Amgen&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) announced new data from the Phase 3 MINT trial of Uplizna&nbsp;(inebilizumab-cdon) for adult patients with <a target="_blank" href="https://www.benzinga.com/25/03/44307450/amgens-uplizna-shows-improved-symptoms-in-patients-with-muscle-weakness-disorder-over-one-year" rel="noreferrer noopener">generalized myasthenia gravis</a>.
The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44301271/uplizna-inebilizumab-cdon-significantly-improves-generalized-myasthenia-gravis-symptoms-in-acetylc" rel="noreferrer noopener">initial loading dose</a>.
The trial demonstrated continued improvement in the efficacy of Uplizna compared to placebo as measured by the change in baseline of Myasthenia Gravis Activities of Daily Living (MG-ADL) score in the AChR+ subpopulation through week 52.
Price Action: AZN stock is up 1.45% at $$74.06 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46175777/fda-flags-major-safety-concerns-for-argenxs-nerve-disorder-drug-stock-falls" target="_blank" rel="noreferrer noopener">FDA Flags Major Safety Concerns For Argenx&#8217;s Nerve Disorder Drug, Stock Falls</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Biotech

Large Cap

Health Care

General

AMGN

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

BMNR

BitMine Immersion Technologies shares are trading higher after the company announced its Ethereum holdings have surpassed $2 billion.

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Market Perform and raises the price target from $167 to $170.

Keefe, Bruyette & Woods Maintains Market Perform on Raymond James Finl, Raises Price Target to $170

Press Releases

Bit Origin Ltd Announces Receipt of Delinquency Notification Letter From Nasdaq Relating to Non-Compliance with Listing Rule 5250(c)(1)

Bit Origin Ltd Regains Compliance with Nasdaq Listing Rule 5250(c)(1)

Bit Origin Ltd Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Bit Origin Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

1606 Corp's (OTC: CBDW) AI to Disrupt $327.6B Gas Station Store & $1.2T Waste Management Industries

Bit Origin Ltd Announces Court Hearing on June 5, 2025, for Share Capital Reduction

Bit Origin Ltd Regains Compliance with Nasdaq Listing Requirements of Minimum Stockholders' Equity

Bit Origin Secures $500 Million Equity and Debt Facilities to Launch Dogecoin Treasury

Bit Origin Acquires Over 40 Million Dogecoin (DOGE) to Advance Treasury Strategy

Comments

Bit Origin

Bit Origin (BTOG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL